



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/692764-Conf. #8952
Filing Date	October 24, 2003
First Named Inventor	Stuart B. LEVY
Art Unit	1614 1636
Examiner Name	Not Yet Assigned Makar
Attorney Docket Number	PAZ-205CP

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/KMI/	A1*	US-5,563,130	10-08-1996	Backer et al.	
	A2*	US-5,567,963	10-22-1996	Rao	
	A3*	US-5,574,026	11-12-1996	Backer, et al.	
	A4*	US-5,668,122	09-16-1997	Fife et al.	
	A5*	US-5,837,696	11-17-1998	Golub et al.	
	A6*	US-5,843,925	12-01-1998	Backer et al.	
	A7*	US-5,843,995	12-01-1998	Rana et al.	
	A8*	US-5,856,315	01-05-1999	Backer et al.	
	A9*	US-5,900,235	05-04-1999	Gosselin et al.	
	A10*	US-6,100,248	08-08-2000	Golub et al.	
	A11*	US-6,642,270-A1	04-18-2002	Nelson et al.	
	A12*	US-20020045603-A1	04-18-2002	Golub et al.	
	A13*	US-6,818,634-A1	08-01-2002	Nelson et al.	
	A14*	US-20020128237-A1	09-12-2002	Nelson et al.	
	A15*	US-20020128238-A1	09-12-2002	Nelson et al.	
	A16*	US-20020132798-A1	09-19-2002	Nelson et al.	
	A17*	US-6,500,812-A1	12-31-2002	Nelson et al.	
	A18*	US-6,841,546-A1	05-29-2003	Draper et al.	
	A19*	US-6,846,939-A1	07-03-2003	Nelson et al.	
	A20*	US-20030166585-A1	09-04-2003	Draper et al.	
	A21*	US-6,617,318	09-09-2003	Nelson, M.L., et al.	
	A22*	US-6,624,168	09-23-2003	Nelson, M.L., et al.	
	A23*	US-20030186281-A1	10-02-2003	Hillen	
	A24*	US-20030215873-A1	11-20-2003	Alekshun et al.	
	A25*	US-20030219407-A1	11-27-2003	Ding et al.	
	A26*	US-6,683,068	01-27-2004	Nelson, M.L., et al.	
	A27*	US-20040033996-A1	02-19-2004	Nelson et al.	
	A28*	US-20040048835-A1	03-11-2004	Nelson et al.	
	A29*	US-20040063674-A1	04-01-2004	Levy et al.	
	A30*	US-20040092490-A1	05-13-2004	Draper et al.	
	A31*	US-20040138183-A1	07-15-2004	Nelson et al.	
	A32*	US-20040152674-A1	08-05-2004	Levy et al.	
	A33*	US-20040157806-A1	08-12-2004	Nelson et al.	
	A34*	US-20040214801-A1	10-28-2004	Nelson et al.	
	A35*	US-6,818,635	11-16-2004	Nelson, Mark L., et al.	
	A36*	US-20040242548-A1	12-02-2004	Draper et al.	
	A37*	US-6,833,365-A1	12-21-2004	Levy et al.	
	A38*	US-20040266740-A1	12-30-2004	Huss et al.	
	A39*	US-20050020545-A1	01-27-2005	Draper et al.	
	A40*	US-6,849,615-A1	02-01-2005	Nelson et al.	
	A41*	US-20050026875-A1	02-03-2005	Nelson et al.	
	A42*	US-20050026876-A1	02-03-2005	Nelson et al.	
	A43*	US-20050038002-A1	02-17-2005	Nelson et al.	
	A44*	US-20050070510-A1	03-31-2005	Draper et al.	
	A45*	US-20050119235-A1	06-02-2005	Nelson et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/692764-Conf. #8952	
			Filing Date	October 24, 2003	
			First Named Inventor	Stuart B. LEVY	
			Art Unit	1614 1636	
			Examiner Name	Not Yet Assigned Makar	
Sheet	2	of	3	Attorney Docket Number	PAZ-205CP

/KM/	A46*	US-20050137174-A1	06-23-2005	Ohemeng et al.	
	A47*	US-20050143352-A1	06-30-2005	Nelson et al.	
	A48*	US-20050143353-A1	06-30-2005	Nelson et al.	
	A49*	US-20050148551-A1	07-07-2005	Nelson et al.	
	A50*	US-20050187198-A1	08-25-2005	Nelson et al.	
	A51*	US-20050215532-A1	09-29-2005	Levy et al.	
	A52*	US-20050250744-A1	11-10-2005	Levy et al.	
	A53*	US-20050288262-A1	12-29-2005	Bandarage et al.	
	A54*	US-7,001,918-A1	02-21-2006	Huss et al.	
	A55*	US-7,045,507-A1	05-16-2006	Draper et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
/KM/ ↓ ↓ ↓	B1	WO-92/12717-A2		08-06-1992	Brem, Henry et al.		
	B2	WO-98/31224-A1		07-23-1998	The Research Foundation of State University of New York et al.		
	B3	WO-99/49871-A1		10-07-1999	The Research Foundation of State University of New York		
	B4	WO-00/28983-A1		05-25-2000	Collagenex Pharmaceuticals, Inc.		
	B5	WO-01/87823-A1		11-22-2001	Collagenex Pharmaceuticals, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/KM/	C1	Amin, A.R. et al, "Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines," <i>FEBS</i> , Vol. 410(2):259-264 (1997)		
	C2	Friedman, Kenneth J. et al, "Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides," <i>The Journal of Biological Chemistry</i> , Vol. 274(51):36193-36199 (1999)		
	C3	Hertweck, Maren et al, "Inhibition of nuclear pre-mRNA splicing by antibiotics <i>in vitro</i> ," <i>Eur. J. Biochem.</i> , Vol. 269:175-183 (2002)		
	C4	Karras, James G. et al, "Deletion of Individual Exons and Induction of Soluble Murine Interleukin-5 Receptor- α Chain Expression through Antisense Oligonucleotide-Mediated Redirection of Pre-mRNA Splicing," <i>Molecular Pharmacology</i> , Vol. 58:380-387 (2000)		
	C5	Krawczak, Michael et al, "The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: Causes and consequences," <i>Human Genetics</i> , Vol. 90(1-2):41-54 (1992)		
Examiner Signature			Date Considered	

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/692764-Conf. #8952	
			Filing Date	October 24, 2003	
			First Named Inventor	Stuart B. LEVY	
			Art Unit	1614 1636	
			Examiner Name	Not Yet Assigned Makar	
Sheet	3	of	3	Attorney Docket Number	PAZ-205CP

/KM	C6	Lim, Sharlene R. et al, "Modulation of Survival Motor Neuron Pre-mRNA Splicing by Inhibition of Alternative 3' Splice Site Pairing," <i>The Journal of Biological Chemistry</i> , Vol. 276(48):45476-45483 (2001)	
	C7	Liu, Y. et al, "Inhibition of in vitro splicing of a group I intron of <i>Pneumocystis carinii</i> ," <i>J. Euk. Microbiol.</i> , Vol. 41:31-38 (1994)	
	C8	Nakai, K. et al, "Construction of a novel database containing aberrant splicing mutations of mammalian genes," <i>Gene</i> , Vol. 141(2):171-177 (1994)	
	C9	Nelson, M. et al, "Tetracyclines in Biology, Chemistry and Medicine," Published by Birkhäuser, pp. 177-196 (2001)	
	C10	Philips, A.V. et al, "RNA processing and human disease," <i>Cellular and Molecular Life Sciences</i> , Vol. 57(2):235-249 (2000)	
	C11	Sazani, Peter et al, "Systemically delivered antisense oligomers upregulate gene expression in mouse tissue," <i>Nature Biotechnology</i> , Vol. 20:1228-1233 (2002)	
	C12	Sazani, Peter et al, "Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs," <i>Nucleic Acids Research</i> , Vol. 29(19):3965-3974 (2001)	
	C13	Schroeder, Renée et al, "Modulation of RNA function by aminoglycoside antibiotics," <i>The EMBO Journal</i> , Vol. 19(1):1-9 (2000)	
	C14	Stoss, Oliver et al, "Misregulation of pre-mRNA splicing that causes human diseases. Concepts and therapeutic strategies," <i>Gene Therapy and Molecular Biology</i> , Vol. 5:9-30 (2000)	
	C15	Wei, Yi et al, "Tetracycline Induces Stabilization of mRNA in <i>Bacillus subtilis</i> ," <i>Journal of Bacteriology</i> , Vol. 184(4):889-894 (2002)	
	C16	Wilton, S.D. et al, "Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides," <i>Neuromuscular Disorders</i> , Vol. 9(5):330-338 (1999)	
	C17	International Search Report Application No. PCT/US03/33926, dated August 24, 2004	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Kimberly Makar/	Date Considered	04/25/2007
--------------------	------------------	-----------------	------------